OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

RecruitingOBSERVATIONAL
Enrollment

55,000

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
ATTR Amyloidosis
Interventions
OTHER

no intervention

not applicable, this is an observational retrospective data analysis study; no interventions in the study

Trial Locations (26)

55344

COMPLETED

Research Site, Eden Prairie

T2P 4K7

RECRUITING

Research Site, Calgary

Unknown

COMPLETED

Research Site, Beijing

COMPLETED

Research Site, Changsha

COMPLETED

Research Site, Chengdu

COMPLETED

Research Site, Guangzhou

COMPLETED

Research Site, Wuhan

RECRUITING

Research Site, Horsens

RECRUITING

Research Site, Berlin

COMPLETED

Research Site, Tokyo

NOT_YET_RECRUITING

Research Site, Lisbon

NOT_YET_RECRUITING

Research Site, Porto

COMPLETED

Research Site, A Coruña

COMPLETED

Research Site, Barcelona

COMPLETED

Research Site, Bilbao

COMPLETED

Research Site, El Palmar

COMPLETED

Research Site, Huelva

COMPLETED

Research Site, Las Palmas de Gran Canaria

COMPLETED

Research Site, Madrid

COMPLETED

Research Site, Majadahonda

COMPLETED

Research Site, Palma de Mallorca

COMPLETED

Research Site, Salamanca

COMPLETED

Research Site, Valencia

COMPLETED

Research Site, Södertälje

RECRUITING

Research Site, Umeå

COMPLETED

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06355934 - OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis | Biotech Hunter | Biotech Hunter